Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07539090 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 6 more changesShow less
    • Final enrollment: 27 participants (planned 24)
    • Primary and study completion dates changed from estimate of Oct 2026 to Oct 8, 2026
    • Interventions: Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) (Drug), Vimseltinib (Drug) to Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) (Drug), Vimseltinib (Drug)
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 3 of 7 entries
    • Site details revised
  2. Primary and study completion pushed from Aug 2026 to Oct 2026v5
  3. Start date changed from estimate of Jun 2026 to Jun 5, 2026v4
  4. Primary and study completion pushed from Jun 2026 to Aug 2026
    • Start date: May 2026 to Jun 2026
    v3
  5. Recruitment opened
    • Study sites: 0 to 1
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
Trial Details
NCT Number NCT07539090
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions
(from sponsor)		 Healthy Participants
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov